JP2016531949A5 - - Google Patents

Download PDF

Info

Publication number
JP2016531949A5
JP2016531949A5 JP2016546191A JP2016546191A JP2016531949A5 JP 2016531949 A5 JP2016531949 A5 JP 2016531949A5 JP 2016546191 A JP2016546191 A JP 2016546191A JP 2016546191 A JP2016546191 A JP 2016546191A JP 2016531949 A5 JP2016531949 A5 JP 2016531949A5
Authority
JP
Japan
Prior art keywords
salt
composition
olopatadine
mometasone
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016546191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016531949A (ja
JP6419195B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2014/065035 external-priority patent/WO2015049665A1/en
Publication of JP2016531949A publication Critical patent/JP2016531949A/ja
Publication of JP2016531949A5 publication Critical patent/JP2016531949A5/ja
Application granted granted Critical
Publication of JP6419195B2 publication Critical patent/JP6419195B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016546191A 2013-10-04 2014-10-03 モメタゾンおよびオロパタジンの組み合わせを使用するアレルギー性鼻炎の治療 Active JP6419195B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3174MU2013 2013-10-04
IN3174MUM2013 2013-10-04
PCT/IB2014/065035 WO2015049665A1 (en) 2013-10-04 2014-10-03 Treatment of allergic rhinitis using a combination of mometasone and olopatadine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018076047A Division JP6768733B2 (ja) 2013-10-04 2018-04-11 モメタゾンおよびオロパタジンの組み合わせを使用するアレルギー性鼻炎の治療

Publications (3)

Publication Number Publication Date
JP2016531949A JP2016531949A (ja) 2016-10-13
JP2016531949A5 true JP2016531949A5 (https=) 2016-11-24
JP6419195B2 JP6419195B2 (ja) 2018-11-07

Family

ID=51982657

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016546191A Active JP6419195B2 (ja) 2013-10-04 2014-10-03 モメタゾンおよびオロパタジンの組み合わせを使用するアレルギー性鼻炎の治療
JP2018076047A Active JP6768733B2 (ja) 2013-10-04 2018-04-11 モメタゾンおよびオロパタジンの組み合わせを使用するアレルギー性鼻炎の治療
JP2020028523A Pending JP2020097624A (ja) 2013-10-04 2020-02-21 モメタゾンおよびオロパタジンの組み合わせを使用するアレルギー性鼻炎の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018076047A Active JP6768733B2 (ja) 2013-10-04 2018-04-11 モメタゾンおよびオロパタジンの組み合わせを使用するアレルギー性鼻炎の治療
JP2020028523A Pending JP2020097624A (ja) 2013-10-04 2020-02-21 モメタゾンおよびオロパタジンの組み合わせを使用するアレルギー性鼻炎の治療

Country Status (12)

Country Link
US (1) US10646500B2 (https=)
EP (2) EP2922553A1 (https=)
JP (3) JP6419195B2 (https=)
CN (2) CN112773808A (https=)
HK (1) HK1215674A1 (https=)
MX (2) MX2015009429A (https=)
MY (1) MY176808A (https=)
PH (1) PH12015502302A1 (https=)
RU (1) RU2686670C2 (https=)
UA (1) UA120587C2 (https=)
WO (1) WO2015049665A1 (https=)
ZA (1) ZA201504740B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9937189B2 (en) 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US10548907B2 (en) 2013-10-04 2020-02-04 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10016443B2 (en) 2013-10-04 2018-07-10 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
CN112773808A (zh) * 2013-10-04 2021-05-11 格兰马克专业公司 使用莫米松和奥洛他定的组合治疗过敏性鼻炎
US10653661B2 (en) 2013-10-04 2020-05-19 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US11679210B2 (en) 2014-10-03 2023-06-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
MX384555B (es) * 2017-06-28 2025-03-14 Glenmark Specialty Sa Dispositivo dispensador y composicion farmaceutica para el tratamiento de la rinitis.
SG11202112592YA (en) * 2018-02-23 2021-12-30 Glenmark Specialty Sa Treatment of allergic rhinitis in pediatric subjects using a combination of mometasone and olopatadine
US12303635B2 (en) 2018-04-16 2025-05-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8520662D0 (en) 1985-08-17 1985-09-25 Wellcome Found Tricyclic aromatic compounds
US4923892A (en) 1985-08-17 1990-05-08 Burroughs Wellcome Co. Tricyclic aromatic compounds
US6127353A (en) 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
PE44995A1 (es) 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
AU7859800A (en) 1999-10-08 2001-04-23 Schering Corporation Topical nasal treatment
US7977376B2 (en) 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
BR0316203A (pt) * 2002-11-12 2005-10-04 Alcon Inc Uso de um agente antialérgico e um esteróide para tratar rinite alérgica
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
AU2005309951B2 (en) 2004-11-24 2011-07-07 Alcon, Inc. Method of delivering nasal spray
DK1919450T3 (da) * 2005-09-01 2014-09-15 Meda Ab Antihistamin- og corticosteroidholdig liposomsammensætning og dens anvendelse til fremstilling af et lægemiddel til behandling af rhinitis og beslægtede lidelser
EP1968548A2 (en) 2005-12-02 2008-09-17 Elan Pharma International Limited Mometasone compositions and methods of making and using the same
BRPI0710654B1 (pt) 2006-04-21 2021-11-03 Toko Yakuhin Kogyo Kabushiki Kaisha Preparação de adesivo para pele/mucosa do tipo gel, pulverizável, e sistema de administração usando a preparação
EP2173169B1 (en) * 2007-06-28 2014-05-21 CyDex Pharmaceuticals, Inc. Nasal delivery of aqueous corticosteroid solutions
WO2010009028A1 (en) * 2008-07-15 2010-01-21 Schering Corporation Intranasal compositions comprising a decongestant and a corticosteroid
WO2010025236A1 (en) 2008-08-27 2010-03-04 Alexander Goldin Composition and method for treating colds
EP2453872B1 (en) 2009-07-17 2013-08-21 Alcon Research, Ltd. Olopatadine nasal spray regimen for children
CN102078285A (zh) * 2009-11-26 2011-06-01 天津金耀集团有限公司 含有皮质激素和h1受体拮抗剂的鼻用原位凝胶
CN102078326A (zh) * 2009-11-26 2011-06-01 天津金耀集团有限公司 含有聚维酮碘与糠酸莫米松的局部使用组合物
WO2011141929A2 (en) 2010-05-11 2011-11-17 Cadila Healthcare Limited Aqueous pharmaceutical compositions of fluticasone and olopatadine
EP2736491B1 (en) 2011-01-04 2017-04-05 Bausch & Lomb Incorporated Bepotastine compositions
AU2013336576A1 (en) 2012-10-25 2015-04-30 Novozymes A/S Improved method for manual dish wash
KR20140081925A (ko) * 2012-12-12 2014-07-02 한미약품 주식회사 코르티코스테로이드, 항히스타민제 및 스테비아를 포함하는 고미 차폐된 약학 제제
HRP20211515T1 (hr) * 2013-09-13 2021-12-24 Glenmark Specialty S.A. Stabilni farmaceutski pripravak u fiksnoj dozi koji sadrži mometazon i olopatadin, namijenjen nazalnoj primjeni
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
CN112773808A (zh) * 2013-10-04 2021-05-11 格兰马克专业公司 使用莫米松和奥洛他定的组合治疗过敏性鼻炎

Similar Documents

Publication Publication Date Title
JP2016531949A5 (https=)
Pham et al. Strategies for the design of orally bioavailable antileishmanial treatments
JP2016523862A5 (https=)
JP2010132695A5 (https=)
MX2017003102A (es) Formulacion para inhalacion liquida que comprende rpl554.
ME02841B (me) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
JP2017506624A5 (https=)
EA201890196A1 (ru) Композиция для устранения заложенности носа, обладающая противовирусным действием
MX2015013965A (es) Composicion farmaceutica de dosis fija estable que comprende mometasona y olopatadina.
RU2015128496A (ru) Лечение аллергического ринита с использованием комбинации мометазона и олопатадина
PH12017502087A1 (en) Tiotropium inhalation solution for nebulization
DOP2022000093A (es) Inhibidores de adrenoreceptor adrac2
BR112015025804A2 (pt) derivados de glutarimida, uso dos mesmos, composição farmacêutica com base neles e métodos para a produção de derivados de glutarimida
BR112015014174A2 (pt) composição de vacina para indivíduos virgens
EP3424512A4 (en) USE OF ALGIN SULFATE IN THE MANUFACTURE OF MEDICAMENTS AND HEALTH CARE PRODUCTS FOR THE PREVENTION AND TREATMENT OF ILLNESSES DUE TO HUMAN PAPILLOMA VIRUSES
JP2017505809A5 (https=)
JP2016502991A5 (https=)
JP2014520874A5 (https=)
EA201201393A1 (ru) Ингалятор, разработанный для доставки лекарственного средства в виде сухого порошка
MX2018013475A (es) Acido carboxilico para tratar/prevenir congestion nasal.
JP2019529569A5 (https=)
JP2017061488A5 (https=)
JP2016175884A5 (https=)
JP2016528283A5 (https=)
HRP20250411T1 (hr) Liječenje alergijskog rinitisa kod pedijatrijskih subjekata kombinacijom mometazona i olopatadina